Chemotherapy, Adjuvant

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • 'I'll do what they did": social norm information and cancer treatment decisions. 
  • A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer. 
  • A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer. 
  • A general formulation for a one-sided group sequential design. 
  • A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. 
  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. 
  • A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. 
  • A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 
  • A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases. 
  • A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. 
  • A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. 
  • Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. 
  • Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. 
  • Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Adherence to adjuvant endocrine therapy for breast cancer: importance in women with low income. 
  • Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. 
  • Adjunctive brexpiprazole for the treatment of major depressive disorder. 
  • Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported? 
  • Adjuvant Chemotherapy for Stage II Rectal Cancer. 
  • Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. 
  • Adjuvant chemotherapy for colorectal hepatic metastases: role of route of administration and timing. 
  • Adjuvant chemotherapy for non-small cell lung cancer. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adjuvant chemotherapy for patients with primary hepatocellular carcinoma: a meta-analysis. 
  • Adjuvant chemotherapy for t1 node-positive colon cancers provides significant survival benefit. 
  • Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma. 
  • Adjuvant chemotherapy prior to postoperative concurrent chemoradiotherapy for locoregionally advanced head and neck cancer. 
  • Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. 
  • Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. 
  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. 
  • Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. 
  • Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer. 
  • Adjuvant therapy for colorectal cancer. 
  • Adjuvant therapy for pancreatic cancer: current status and future directions. 
  • Adjuvant therapy for surgically resected pancreatic adenocarcinoma. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Adjuvant therapy of pancreatic cancer. 
  • Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. 
  • Adjuvant trazodone in the treatment of alcoholism: an open study. 
  • Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. 
  • Adrenocortical carcinoma. 
  • Aggressive multimodality treatment of invasive thymic carcinoma. 
  • An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. 
  • Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. 
  • Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? 
  • Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. 
  • Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. 
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. 
  • Assessment of multimodality therapy use for extremity sarcoma in the United States. 
  • Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. 
  • Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. 
  • Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. 
  • BMI influences prognosis following surgery and adjuvant chemotherapy for lymph node positive breast cancer. 
  • Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. 
  • Bevacizumab and wound-healing complications: mechanisms of action, clinical evidence, and management recommendations for the plastic surgeon. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. 
  • Borderline ovarian tumors: current concepts for prognostic factors and clinical management. 
  • Cancer care quality measures: diagnosis and treatment of colorectal cancer. 
  • Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification. 
  • Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. 
  • Cardiorespiratory fitness in breast cancer patients: a call for normative values. 
  • Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer. 
  • Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. 
  • Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. 
  • Characteristics associated with swallowing changes after concurrent chemotherapy and radiotherapy in patients with head and neck cancer. 
  • Chemoradiation for localized pancreatic cancer: another perspective. 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapy for adults with malignant glioma. 
  • Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). 
  • Clear cell adenocarcinoma in a female urethral diverticulum. 
  • Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. 
  • Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). 
  • Colorectal cancer: adjuvant chemotherapy for rectal cancer-an unresolved issue. 
  • Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. 
  • Combined treatment approaches in regionally advanced bladder cancer. 
  • Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. 
  • Combining targeted agents with modern radiotherapy in soft tissue sarcomas. 
  • Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). 
  • Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. 
  • Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. 
  • Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). 
  • Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. 
  • Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. 
  • Concurrent chemotherapy and re-irradiation for locoregionally recurrent head and neck cancer. 
  • Congenital neuroepithelioma in an infant hand. 
  • Controversies in the treatment of prostate cancer with maximal androgen deprivation. 
  • Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix. 
  • Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. 
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. 
  • Current Trends in the Management of Ductal Carcinoma In Situ. 
  • Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis. 
  • Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. 
  • Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. 
  • DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. 
  • Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. 
  • Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? 
  • Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy. 
  • Determining the Optimal Timing for Initiation of Adjuvant Chemotherapy After Resection for Stage II and III Colon Cancer. 
  • Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. 
  • Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. 
  • Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? 
  • Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study. 
  • Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. 
  • Early breast cancer therapy and cardiovascular injury. 
  • Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. 
  • Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. 
  • Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. 
  • Effect of esthetic outcome after breast-conserving surgery on psychosocial functioning and quality of life. 
  • Effect of neoadjuvant chemoradiation on operative mortality and morbidity for pancreaticoduodenectomy. 
  • Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. 
  • Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. 
  • Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. 
  • Effects of chemotherapy and tamoxifen on cervical and vaginal smears in bone marrow transplant recipients. 
  • Efficacy of autologous blood injection for treating overfiltering or leaking blebs after glaucoma surgery. 
  • Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). 
  • Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. 
  • Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram. 
  • Evolution of therapeutic approaches with luteinizing hormone-releasing hormone agonists in 2003. 
  • Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection. 
  • Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials. 
  • Extent of neck dissection required after concurrent chemoradiation for stage IV head and neck squamous cell carcinoma. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. 
  • Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. 
  • Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors. 
  • Fibromatoses in childhood: the desmoid/fibromatosis complex. 
  • Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901. 
  • Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer. 
  • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. 
  • Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. 
  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. 
  • Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. 
  • Identification of distinct and overlapping cortical areas for bilingual naming and reading using cortical stimulation. Case report. 
  • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. 
  • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. 
  • Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. 
  • Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 
  • Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. 
  • Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. 
  • Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. 
  • Impact of postoperative nausea and vomiting prophylaxis with dexamethasone on the risk of recurrence of endometrial cancer. 
  • Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Improving understanding of adjuvant therapy options by using simpler risk graphics. 
  • Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. 
  • Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. 
  • Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Individual responses to chemotherapy-induced oxidative stress. 
  • Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. 
  • Induction chemotherapy: to use or not to use? That is the question. 
  • Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer. 
  • Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. 
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 
  • Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. 
  • Initiation of salvage therapy for prostate cancer. 
  • Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. 
  • Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. 
  • Invited commentary. 
  • Is NNT AOK? 
  • Is a reduction in radiation lung volume and dose necessary with paclitaxel chemotherapy for node-positive breast cancer? 
  • Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. 
  • Isolated tumor cells in breast cancer. 
  • Laser suture lysis after mitomycin C trabeculectomy. 
  • Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. 
  • Liver metastases from breast cancer: long-term survival after curative resection. 
  • Local failure in resected N1 lung cancer: implications for adjuvant therapy. 
  • Locally advanced pancreatic cancer. 
  • Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis. 
  • Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. 
  • Long-term results of therapy for stage C neuroblastoma. 
  • Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. 
  • Long-term survival following total sacrectomy with reconstruction for the treatment of primary osteosarcoma of the sacrum. A case report. 
  • Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. 
  • MSH6 inactivation and emergent temozolomide resistance in human glioblastomas. 
  • Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. 
  • Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. 
  • Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. 
  • Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. 
  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 
  • Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. 
  • Minimally invasive operation for breast cancer. 
  • Mitomycin C-augumented trabeculectomy with postoperative wound modulation in pediatric glaucoma. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. 
  • Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. 
  • Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. 
  • Myeloid growth factors. 
  • NCCN clinical practice guidelines in oncology: kidney cancer. 
  • Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. 
  • Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. 
  • Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. 
  • Neoadjuvant therapy for pancreatic cancer: the Duke experience. 
  • Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. 
  • Never too old? Age should not be a barrier to enrollment in cancer clinical trials. 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Non-vena cava venous leiomyosarcomas: a review of the literature. 
  • Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience. 
  • ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY. 
  • Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. 
  • Outcomes in surgical stage I uterine papillary serous carcinoma. 
  • Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. 
  • Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. 
  • Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor. 
  • Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. 
  • Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. 
  • Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. 
  • Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force. 
  • Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. 
  • Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Patterns of care analysis among women with ductal carcinoma in situ in North Carolina. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Pediatric melanoma. 
  • Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. 
  • Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. 
  • Peritoneal carcinomatosis in patients with gastric cancer, and the role for surgical resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. 
  • Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 
  • Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. 
  • Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. 
  • Phase I evaluation of doxorubicin and whole-body hyperthermia in dogs with lymphoma. 
  • Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. 
  • Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. 
  • Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. 
  • Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. 
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. 
  • Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. 
  • Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Predictors of Long-Term Quality of Life for Survivors of Stage II/III Rectal Cancer in the Cancer Care Outcomes Research and Surveillance Consortium. 
  • Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). 
  • Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. 
  • Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. 
  • Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. 
  • Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. 
  • Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. 
  • Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. 
  • Preoperative infusional chemoradiation and surgery with or without an electron beam intraoperative boost for advanced primary rectal cancer. 
  • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. 
  • Preoperative radiotherapy for rectal cancer: benefits and controversies. 
  • Primary pediatric intraspinal sarcomas. Report of 3 cases. 
  • Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. 
  • Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients. 
  • Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). 
  • Publication policy, informed consent, and the randomized clinical trial. 
  • Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation. 
  • Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review. 
  • Quality of life after adjuvant chemotherapy for breast cancer. 
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. 
  • Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. 
  • Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. 
  • Radiation therapy in the treatment of cholangiocarcinoma. 
  • Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer. 
  • Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. 
  • Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer. 
  • Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. 
  • Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Risk factors for hypopharyngeal/upper esophageal stricture formation after concurrent chemoradiation. 
  • Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. 
  • Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. 
  • Role of radiation therapy in patients with resectable pancreatic cancer. 
  • Routine Admission to Intensive Care Unit After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy: Not Always a Requirement. 
  • Routine use of zoledronic acid in early-stage breast cancer. 
  • Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: a phase II randomized trial. 
  • Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. 
  • Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 
  • Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. 
  • Simultaneously detected bilateral testicular cancer of different histopathological origin--a challenging situation for the urologist. 
  • Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. 
  • Social support and its implications in older, early-stage breast cancer patients in CALGB 49907 (Alliance A171301). 
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. 
  • Sphincter-sparing treatment for distal rectal adenocarcinoma. 
  • Squamous cell carcinoma of the oropharynx and hypopharynx. 
  • Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy. 
  • Staging of pancreatic cancer before and after neoadjuvant chemoradiation. 
  • Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. 
  • Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer. 
  • Surgery, hyperfractionated craniospinal irradiation, and adjuvant chemotherapy in the management of supratentorial embryonal neuroepithelial neoplasms in children. 
  • Surgical management of cutaneous melanoma: current practice and impact on prognosis. 
  • Surgical strategies and outcomes after induction therapy for non-small cell lung cancer. 
  • Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment. 
  • Systemic therapy for older women with breast cancer. 
  • T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment. 
  • Testicular cancer. Clinical practice guidelines. 
  • The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy. 
  • The Cervix Cancer Research Network: A Global Outreach Effort on Behalf of the Gynecologic Cancer InterGroup. 
  • The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). 
  • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. 
  • The benefits of discussing adjuvant therapies one at a time instead of all at once. 
  • The clinical management of chondrosarcoma. 
  • The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. 
  • The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma. 
  • The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer. 
  • The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. 
  • The impact of sharing results of a randomized breast cancer clinical trial with study participants. 
  • The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. 
  • The role of androgen deprivation therapy combined with prostate brachytherapy. 
  • The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. 
  • The role of optimal debulking in advanced stage serous carcinoma of the uterus. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. 
  • Thirty years of rectal cancer research: a brief history. 
  • Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. 
  • Thrombosis and drug-eluting stents: an objective appraisal. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. 
  • Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. 
  • Total neoadjuvant therapy for rectal cancer: An emerging option. 
  • Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. 
  • Treatment Factors Associated With Survival in Early-Stage Oral Cavity Cancer: Analysis of 6830 Cases From the National Cancer Data Base. 
  • Treatment and outcome of 82 patients with angiosarcoma. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. 
  • Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival. 
  • Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States. 
  • Treatment-induced changes in vocal cord mobility and subsequent local recurrence after organ preservation therapy for laryngeal carcinoma. 
  • Undertreatment of obese women receiving breast cancer chemotherapy. 
  • Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. 
  • Use of 1,25α dihydroxyvitamin D3 as a cryosensitizing agent in a murine prostate cancer model. 
  • Use of molecular biomarkers to inform adjuvant therapy for colon cancer. 
  • Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy. 
  • Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? 
  • Well differentiated astrocytoma occurring nine years after radiation therapy for medulloblastoma. 
  • What threshold for adjuvant therapy in older breast cancer patients? 
  • Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? 
  • Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. 
  • [Adjuvant therapy of surgically removed stage I melanoma]. 
  • [Primary chemotherapy in the treatment of breast cancer]. 
  • [Treatment of primary cancer of the breast in elderly women. Role of hormone therapy]. 
• 

  Keywords of People

  • Abbruzzese, James, Charles Johnson, M.D. Professor of Medicine, Medicine, Medical Oncology
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Berchuck, Andrew, James M. Ingram Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Cohen, Seth Morris, Associate Professor of Surgery, Surgery, Head and Neck Surgery and Communication Sciences
  • Cohen-Wolkowiez, Michael, Professor of Pediatrics, Pediatrics, Infectious Diseases
  • Craciunescu, Oana, Associate Professor of Radiation Oncology, Radiation Oncology
  • Esclamado, Ramon Mitra, Richard Hall Chaney,Sr. Professor of Otolaryngology, Head & Neck Surgery, in the School of Medicine, Surgery, Head and Neck Surgery and Communication Sciences
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • MacFall, James R., Adjunct Professor in the Department of Radiology, Radiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Cancer Institute
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Sosa, Julie Ann, Professor of Surgery, Medicine, Medical Oncology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology, Nuclear Medicine